¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high mobility group proteins"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɺλý°Ë
  • high temperature sterilization
    °í¿Â¸ê±Õ
  • high tone deafness
    °íÀ½³­Ã»
  • high velocity signal loss
    °í¼Ó½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °íÀü¾Ð¹æ»ç¼±ÃÔ¿µ(¼ú)
  • high zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-fiber diet
    °í¼¶À¯Áú½Ä»ç
  • high-grade
    °íµµ
  • high-grade squamous intraepithelial lesion
    °íµî±ÞÆíÆò»óÇdz»º´ÅÍ
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½É(Àå)ºÎÀü
  • high-pass filter
    °íÁÖÆÄÅë°ú¿©°ú±â, °íÁÖÆÄÅë°ú°Å¸£°³
  • high-performance liquid chromatography
    °í¼º´É¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-pressure liquid chromatography
    °í¾Ð¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • high-protein diet
    °í´Ü¹éÁú½Ä»ç
  • high-tension pulse
    °í±äÀ可¹Ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • end group spine
    ±ê³¡°¡½Ã
  • enteric group
    âÀÚ±Õ±º
  • evocative group therapy
    Ç¥ÇöÁý´Ü¿ä¹ý
  • functional group
    ÀÛ¿ë±â
  • group
    ¹«¸®, ±º, Áý´Ü
  • group-specific
    ±ºÆ¯ÀÌ-
  • glucophore group
    ´ã´ç±â
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù
  • group hospital
    º´¿øÁ¶ÇÕ
  • group medicine
    Áý´ÜÁø·á, Çùµ¿Áø·á
  • group practice
    Áý´Ü°³¾÷
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¹ý)
  • group reference value
    Áý´Ü±âÁØÄ¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • psittacosis-lymphogranuloma-trachoma group
    ¾Þ¹«(»õ)º´(¡­Ü») ¸²ÇÁÀ°¾ÆÁ¾Áõ Æ®¶óÄÚ¸¶±º(¡­ë¿ä´ðþñø¡­ÏØ)
  • psychotherapy, group
    Áý´ÜÁ¤½ÅÄ¡·á.
  • HDL (High-density lipoproteins)
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High-molecular-weight kininogen
    °íºÐÀÚ·®Å°´Ï³ëÁø
  • High-threshold cells
    °í¿ªÄ¡¼¼Æ÷(ÍÔ ö·á¬øà)
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high spinal anesthesia
    °íÀ§Ã´Ã߸¶Ãë(¹ý).
  • high temperature sterlization
    °í¿Â¸ê±Õ.
  • high tension pulse
    °í¾Ð¸Æ(ÍÔäâØæ), °íÀ可(ÍÔí娿).
  • high tone deafness
    °íÀ½¼º³­Ã»
  • high tracheostomy
    »ó±â°üÀý°³¼ú
  • high vacuum
    °íÁø°ø(°íÁø°ø).
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high ventricular septal defect
    °íÀ§½É½ÇÁ߰ݰá¼Õ.
  • high vitamin diet
    °íºñŸ¹Î½ÄÀÌ.
  • high voltage radiography
    °íÀü¾Ð ÃÔ¿µ¼ú
  • high volume sampler
    ÇÏÀ̺¼·ý»ùÇ÷¯.
  • high-altitude illness
    °í¼Ò¼ºÁúº´
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
  • high-performance liquid chromatography
    °íÀÛÀ§(íÂêÓ)¾×üũ·Î¸¶Åä±×¶óÇÇ
  • high-power applications
    °íÃâ·Â Àû¿ë (ÍÔõóÕô îêéÄ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • Gm group
    Gm ±â(Ðñ)
  • group specificity
    ±â(Ðñ) ƯÀ̼º(÷åì¶àõ)
  • group transfer reaction
    ¿øÀÚ´Ü ÀüÀÌ ¹ÝÀÀ(ê«í­Ó¥ï®ì¹Úãëë)
  • group transfer potential
    ¿øÀÚ´Ü ÀüÀÌ ÀüÀ§(ê«í­Ó¥ï®ì¹Úãëë)
  • group translocation
    ¹«¸® ÀüÀ§(ï®êÈ)
  • guanidinium group
    ±¸¾Æ´Ïµð´Ï¿ò±â(Ðñ)
  • guanidino group
    ±¸¾Æ´Ïµð³ë±â(Ðñ)
  • guanido group
    ±¸¾Æ´Ïµµ±â(Ðñ)
  • haptenic group
    ÇÕÅÙ±â(Ðñ)
  • hydroxyl group
    ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • hydroxymethyl group
    ÇÏÀ̵å·Ï½Ã¸ÞÆ¿±â(Ðñ)
  • hypsochromic group
    û»öÀ̵¿±â(ôìßäì¹ÔÑÐñ)
  • imidazole group
    À̴̹ÙÁ¹±â(Ðñ)
  • imino group
    À̹̳ë±â(Ðñ)
  • Inv group
    Inv ±º(ÏØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
GT gait training; galactosyl transferase; gastrostomy; generation time; genetic therapy; gingiva treatm...
MN a blood group in the MNSs blood group system; malignant nephrosclerosis; Master of Nursing; meganewt...
HDG high-dose group
HCD health care delivery; heavy-chain disease; high-calorie diet; high-carbohydrate diet; homologous can...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
EMSA Electrophoretic Mobility Shift Assay
EMSA Electrophoretic gel mobility shift assay
E.P.M. Electrophoretic mobility
EMS Electrophoretic mobility shift
EMSA Electrophoretic mobility shift analyses
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
ordinary high water mark <marine biology> That line on the shore established by the fluctuations of water and indicated by physical characteristics such as clear, natural line impressed on the bank, shelving, changes in the character of the soil, destruction of terrestrial vegetation, the presence of litter and debris, or other appropriate means that consider the characteristics of the surrounding areas.
(11 Jan 1998)
technology, high-cost Advanced technology that is costly, requires highly skilled personnel, and is unique in its particular application. Includes innovative, specialised medical/surgical procedures as well as advanced diagnostic and therapeutic equipment.
(12 Dec 1998)
familial high density lipoprotein deficiency Familial high {density lipoprotein deficiency}; a heritable disorder of lipid metabolism characterised by almost complete absence from plasma of high density lipoproteins, and by storage of cholesterol esters in foam cells, tonsillar enlargement, an orange or yellow-gray colour of the pharyngeal and rectal mucosa, hepatosplenomegaly, lymph node enlargement, corneal opacity, and peripheral neuropathy; autosomal recessive inheritance.
Synonym: familial high {density lipoprotein deficiency}, Tangier disease.
Origin: G. An-, priv., + alpha, a, + lipoprotein + -aemia, blood
(05 Mar 2000)
kininogen, high-molecular-weight A plasma protein, molecular weight of 110 kD, that normally exists in plasma in a 1:1 complex with prekallikrein. Hmwk is split by plasma kallikrein to produce bradykinin. The complex is a cofactor in the activation of coagulation factor xii. The product of this reaction, xiia, in turn activates prekallikrein to kallikrein.
(12 Dec 1998)
lymphoma, high-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively unfavorable survival potential.
(12 Dec 1998)
adenovirus e1a proteins Proteins transcribed from the e1a region of adenovirus which are involved in positive regulation of transcription of the early genes.
(12 Dec 1998)
adenovirus e1b proteins Proteins transcribed from the e1b region of adenovirus which are involved in regulation of the levels of early and late gene expression.
(12 Dec 1998)
adenovirus e1 proteins The very first viral gene products synthesised after cells are infected with adenovirus. The e1 region of the genome has been divided into two major transcriptional units, e1a and e1b, each expressing proteins of the same name (adenovirus e1a proteins and adenovirus e1b proteins).
(12 Dec 1998)
adenovirus e2 proteins Proteins transcribed from the e2 region of adenovirus. Several of these are required for viral DNA replication.
(12 Dec 1998)
adenovirus e3 proteins Proteins transcribed from the e3 region of adenovirus but not essential for viral replication. The e3 19k protein mediates adenovirus persistence by reducing the expression of class I major histocompatibility complex antigens on the surface of infected cells.
(12 Dec 1998)
adenovirus e4 proteins Proteins transcribed from the e4 region of adenovirus. The e4 19k protein transactivates transcription of the adenovirus e2f protein and complexes with it.
(12 Dec 1998)
adenovirus early proteins <molecular biology, protein, virology> Proteins encoded by adenoviruses that are synthesised prior to, and in the absence of, viral DNA replication.
The proteins are involved in both positive and negative regulation of expression in viral and cellular genes, and also affect the stability of viral mRNA. Some are also involved in oncogenic transformation.
(12 Dec 1998)
amino acids, peptides, and proteins Amino acids and chains of amino acids connected by peptide linkages.
(12 Dec 1998)
androgen-binding proteins Carrier proteins produced in the sertoli cells of the testis, secreted into the seminiferous tubules, and transported via the efferent ducts to the epididymis. Participate in the transport of androgens; include also synthetic androgens binding proteins.
(12 Dec 1998)
archaeal proteins Proteins found in any species of archaeon.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high boot
    ÀåÈ­
  • high brass
    =top brass
  • high camp
    ¿¹¼úÀûÀ¸·Î ÁøºÎÇÑ °ÍÀ» ÀǵµÀûÀ¸·Î ÀÌ¿ëÇϱâ
  • high chair
    (¾î¸°ÀÌÀÇ)½Ä»ç¿ë ³ôÀº ÀÇÀÚ
  • high color
    ÁÁÀº Ç÷»ö
  • high comedy
    (¿¬±âÀÇ ÀÍ»ì µûÀ§¿¡ ÁßÁ¡À» µÎÁö ¾Ê´Â)°í±ÞÈñ±Ø
  • high command
    ÃÖ°í »ç·ÉºÎ
  • high commissioner
    (½Ä¹ÎÁöÀÇ)°íµî ÆÇ¹«°ü !
  • high crime
    Áß´ëÇÑ ¹üÁË(´ëÅë·É ±âŸ ÇàÁ¤°üÀÇ ÅºÇÙ ÀÌÀ¯°¡ µÇ´Â ÆÄ·ÅÄ¡ ¹üÁË)
  • high day
    ÃàÁ¦ÀÏ
  • high day
    ÃàÁ¦ÀÏ;°æÃàÀÏ
  • high explosive
    °í¼º´É Æø¾à
  • high faluting
    °úÀåµÈ (¸»)
  • high farming
    Áý¾à³ó¾÷
  • high fashion
    (ÀǺ¹ÀÇ)ÃֽŠÀ¯Çà ½ºÅ¸ÀÏ(µðÀÚÀÎ);ÇÏÀÌ ÆÐ¼Ç;=haute couture
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á